| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Alanine-based spacers promote an efficient antigen processing and presentation in neoantigen polypeptide vaccines
|
Aguilar-Gurrieri, Carmen
|
|
|
72 |
7 |
p. 2113-2125
|
artikel
|
| 2 |
Anti-PD-1 therapy in advanced sarcomas: is cutaneous primary site a stronger predictor of response than histologic subtype?
|
Miao, Ruoyu
|
|
|
72 |
7 |
p. 2521-2527
|
artikel
|
| 3 |
A phase I prospective, non-randomized trial of autologous dendritic cell-based cryoimmunotherapy in patients with metastatic castration-resistant prostate cancer
|
Thomsen, Liv Cecilie Vestrheim
|
|
|
72 |
7 |
p. 2357-2373
|
artikel
|
| 4 |
A randomised controlled trial of long NY-ESO-1 peptide-pulsed autologous dendritic cells with or without alpha-galactosylceramide in high-risk melanoma
|
Dasyam, Nathaniel
|
|
|
72 |
7 |
p. 2267-2282
|
artikel
|
| 5 |
Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy
|
Johns, Andrew C.
|
|
|
72 |
7 |
p. 2005-2013
|
artikel
|
| 6 |
Associations between KIR/KIR-ligand genotypes and clinical outcome for patients with advanced solid tumors receiving BEMPEG plus nivolumab combination therapy in the PIVOT-02 trial
|
Feils, A. S.
|
|
|
72 |
7 |
p. 2099-2111
|
artikel
|
| 7 |
BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia
|
Sordo-Bahamonde, Christian
|
|
|
72 |
7 |
p. 2529-2539
|
artikel
|
| 8 |
Cancer immunity and immunotherapy beyond COVID-19
|
Bellone, Matteo
|
|
|
72 |
7 |
p. 2541-2548
|
artikel
|
| 9 |
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
|
Marcinek, Anetta
|
|
|
72 |
7 |
p. 2499-2512
|
artikel
|
| 10 |
Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma
|
Yamada, Shuhei
|
|
|
72 |
7 |
p. 2057-2065
|
artikel
|
| 11 |
CiTSA: a comprehensive platform provides experimentally supported signatures of cancer immunotherapy and analysis tools based on bulk and scRNA-seq data
|
Li, Feng
|
|
|
72 |
7 |
p. 2319-2330
|
artikel
|
| 12 |
Clinicopathological significance of peritumoral alveolar macrophages in patients with resected early-stage lung squamous cell carcinoma
|
Tanaka, Yu
|
|
|
72 |
7 |
p. 2205-2215
|
artikel
|
| 13 |
Combined therapeutic effect of YHO-1701 with PD-1 blockade is dependent on natural killer cell activity in syngeneic mouse models
|
Takahashi, Hiroyuki
|
|
|
72 |
7 |
p. 2473-2482
|
artikel
|
| 14 |
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
|
Marcinek, Anetta
|
|
|
72 |
7 |
p. 2513-2514
|
artikel
|
| 15 |
Correction to: LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells
|
Wu, Peitao
|
|
|
72 |
7 |
p. 2195-2196
|
artikel
|
| 16 |
Correction to: Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune‑related adverse events among cancer patients
|
Özdemir, Berna C.
|
|
|
72 |
7 |
p. 2003-2004
|
artikel
|
| 17 |
Effectiveness and safety of radiotherapy plus programmed death-1 inhibitors and lenvatinib in patients with advanced biliary tract carcinoma: a real-world study
|
Wang, Yunchao
|
|
|
72 |
7 |
p. 2197-2204
|
artikel
|
| 18 |
Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC
|
Li, Ting
|
|
|
72 |
7 |
p. 2137-2149
|
artikel
|
| 19 |
Efficacy and safety of immune checkpoint inhibitors for hepatocellular carcinoma patients with macrovascular invasion or extrahepatic spread: a systematic review and meta-analysis of 54 studies with 6187 hepatocellular carcinoma patients
|
Han, Cheng-Long
|
|
|
72 |
7 |
p. 1957-1969
|
artikel
|
| 20 |
Efficacy and safety of immune checkpoint inhibitors in elderly patients with primary liver cancer: a retrospective, multicenter, real-world cohort study
|
Xiao, Lushan
|
|
|
72 |
7 |
p. 2299-2308
|
artikel
|
| 21 |
Establishment of a novel NFAT-GFP reporter platform useful for the functional avidity maturation of HLA class II-restricted TCRs
|
Fujiki, Fumihiro
|
|
|
72 |
7 |
p. 2347-2356
|
artikel
|
| 22 |
Expression of soluble CD27 in extranodal natural killer/T-cell lymphoma, nasal type: potential as a biomarker for diagnosis and CD27/CD70-targeted therapy
|
Nagato, Toshihiro
|
|
|
72 |
7 |
p. 2087-2098
|
artikel
|
| 23 |
Factors impacting the efficacy of the in-situ vaccine with CpG and OX40 agonist
|
Pieper, Alexander A.
|
|
|
72 |
7 |
p. 2459-2471
|
artikel
|
| 24 |
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumors
|
Bendell, Johanna
|
|
|
72 |
7 |
p. 2443-2458
|
artikel
|
| 25 |
HER2-targeting antibody–drug conjugate RC48 alone or in combination with immunotherapy for locally advanced or metastatic urothelial carcinoma: a multicenter, real-world study
|
Chen, Meiting
|
|
|
72 |
7 |
p. 2309-2318
|
artikel
|
| 26 |
Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire
|
Millar, Douglas G.
|
|
|
72 |
7 |
p. 2375-2392
|
artikel
|
| 27 |
IL13Rα2-targeted third-generation CAR-T cells with CD28 transmembrane domain mediate the best anti-glioblastoma efficacy
|
Gu, Aiqin
|
|
|
72 |
7 |
p. 2393-2403
|
artikel
|
| 28 |
Immune checkpoint inhibition combined with targeted therapy using a novel virus-like drug conjugate induces complete responses in a murine model of local and distant tumors
|
Huis in ‘t Veld, Ruben V.
|
|
|
72 |
7 |
p. 2405-2422
|
artikel
|
| 29 |
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach
|
Botticelli, Andrea
|
|
|
72 |
7 |
p. 2217-2231
|
artikel
|
| 30 |
Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC
|
Wang, Shasha
|
|
|
72 |
7 |
p. 2423-2442
|
artikel
|
| 31 |
LILRB2-containing small extracellular vesicles from glioblastoma promote tumor progression by promoting the formation and expansion of myeloid-derived suppressor cells
|
Wu, Peitao
|
|
|
72 |
7 |
p. 2179-2193
|
artikel
|
| 32 |
Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy
|
Li, Mingjia
|
|
|
72 |
7 |
p. 2067-2074
|
artikel
|
| 33 |
MIP3α as an early prognostic predictor for patients with B-cell malignancies receiving CD19/CD22-redirected CAR-T cell cocktail therapy
|
Jin, Jin
|
|
|
72 |
7 |
p. 2245-2256
|
artikel
|
| 34 |
Mitochondrial C1QBP is essential for T cell antitumor function by maintaining mitochondrial plasticity and metabolic fitness
|
Tian, Hui
|
|
|
72 |
7 |
p. 2151-2168
|
artikel
|
| 35 |
M2 tumor-associated macrophages resist to oxidative stress through heme oxygenase-1 in the colorectal cancer tumor microenvironment
|
Ito, Misato
|
|
|
72 |
7 |
p. 2233-2244
|
artikel
|
| 36 |
Multidisciplinary recommendations for essential baseline functional and laboratory tests to facilitate early diagnosis and management of immune-related adverse events among cancer patients
|
Özdemir, Berna C.
|
|
|
72 |
7 |
p. 1991-2001
|
artikel
|
| 37 |
Neoadjuvant Camrelizumab for Non-Small Cell Lung Cancer: A Retrospective Multicenter, Real-World Study (CTONG2004)
|
Liu, Si-Yang
|
|
|
72 |
7 |
p. 2257-2265
|
artikel
|
| 38 |
Overcoming cancer-associated fibroblast-induced immunosuppression by anti-interleukin-6 receptor antibody
|
Nishiwaki, Noriyuki
|
|
|
72 |
7 |
p. 2029-2044
|
artikel
|
| 39 |
Pembrolizumab near the end of life in patients with metastatic pancreatic cancer: a multi-site consecutive series to examine survival and patient treatment burden
|
Storandt, Michael H.
|
|
|
72 |
7 |
p. 2515-2520
|
artikel
|
| 40 |
Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia
|
Cheng, Jiali
|
|
|
72 |
7 |
p. 2331-2346
|
artikel
|
| 41 |
Preliminary clinical study of personalized neoantigen vaccine therapy for microsatellite stability (MSS)-advanced colorectal cancer
|
Yu, Yao-Jun
|
|
|
72 |
7 |
p. 2045-2056
|
artikel
|
| 42 |
Risk factors indicating immune-related adverse events with combination chemotherapy with immune checkpoint inhibitors and platinum agents in patients with non-small cell lung cancer: a multicenter retrospective study
|
Fujimoto, Airi
|
|
|
72 |
7 |
p. 2169-2178
|
artikel
|
| 43 |
Targeting CD73 increases therapeutic response to immunogenic chemotherapy by promoting dendritic cell maturation
|
Lin, Yun-Shan
|
|
|
72 |
7 |
p. 2283-2297
|
artikel
|
| 44 |
The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort
|
Nielsen, Tyler J.
|
|
|
72 |
7 |
p. 2075-2086
|
artikel
|
| 45 |
The landscape of objective response rate of anti-PD-1/L1 monotherapy across 31 types of cancer: a system review and novel biomarker investigating
|
Mao, Yize
|
|
|
72 |
7 |
p. 2483-2498
|
artikel
|
| 46 |
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors
|
Perrone, Fabiana
|
|
|
72 |
7 |
p. 2127-2135
|
artikel
|
| 47 |
The role of spatial interplay patterns between PD-L1-positive tumor cell and T cell in recurrence of locally advanced non-small cell lung cancer
|
Yang, Liying
|
|
|
72 |
7 |
p. 2015-2027
|
artikel
|
| 48 |
Tumour microenvironment as a predictive factor for immunotherapy in non-muscle-invasive bladder cancer
|
Semeniuk-Wojtaś, Aleksandra
|
|
|
72 |
7 |
p. 1971-1989
|
artikel
|
Tijdschrift beschrijving